Kangpu Bio-Pharma, a Shanghai clinical stage company, completed a $14 million Pre-B financing. Headquartered in Zhangjiang Hi-Tech Park, Kangpu is focused on developing small molecule drugs targeting immuno-modulating sites to develop treatments for cancer, autoimmune diseases and inflammation. The company has developed proprietary technologies to generate and degrade ubiquitin-protein. It also has a drug discovery combination platform called X-Synergy®. The financing was led by Shenzhen Guozhong Venture Capital and Shanghai Furong Investment. Source: China Biotoday
